OV4Cis Cell Line

Cat. #161760

OV4Cis Cell Line

Cat. #: 161760

Organism: Mouse

Tissue: Ovary

Model: Mutant


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Michelle Lockley

Institute: Queen Mary University of London, UK

Primary Citation: J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200.

Tool Details

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: OV4Cis Cell Line
  • Cancer: Gynaecologic cancer
  • Research fields: Cancer
  • Parental cell: OVCAR4 cell lines
  • Organism: Mouse
  • Gender: Female
  • Tissue: Ovary
  • Growth properties: Adherent
  • Model: Mutant
  • Model description: Platinum-resistant HGSC in vivo cell line
  • Crispr: No
  • Description: Platinum-resistant HGSC cancer cells with a growth advantage in the presence of therapy that expand to create drug-resistant tumours.
  • Production details: Cells were cultured in vitro in increasing concentrations of either cisplatin or carboplatin until an increase in IC50 between two and ten-fold was achieved to reflect the resistance observed in human patients


  • Growth medium: DMEM containing 10% FBS and 1% penicillin/streptomycin. Cells should be cultured without drug but used at low passage to ensure drug resistance is maintained.
  • Temperature: 37° C
  • Cultured in antibiotics: Streptomycin and Penicillin
  • Mycoplasma free: Yes
  • Str profiling: 16 locus STR verification (DNA Diagnostics Centre, London, UK: June 2015?February 2016 and European Collection of Authenticated Cell Lines August 2019)


  • J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200.